ecancer
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
Leukemia
ecancer
Epitope Editing Enables Targeted Immunotherapy of AML
FEATURING
Gabriele Casirati
- 22 views
- October 23, 2023
ecancer
ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for Treatment of R/R CLL and SLL
FEATURING
Jennifer Brown
- 506 views
- January 11, 2023
- 1
ecancer
First Results of a Head-to-Head Trial of Acalabrutinib vs. Ibrutinib in Previously Treated CLL
FEATURING
John Byrd
- 405 views
- October 5, 2022
ecancer
Safety & Efficacy of Asciminib for Heavily Pretreated Patients With CP-CML
FEATURING
Michael J. Mauro
- 26 views
- April 13, 2022
ecancer
EHA 2021 Update on 1L Ibrutinib + Venetoclax for CLL/SLL: Primary Analysis of the CAPTIVATE Study
FEATURING
John Allan
- 22 views
- September 6, 2021
ecancer
EHA 2021 Update on Venetoclax + Obinutuzumab in Untreated CLL: 4-year Follow-Up of the CLL14 Trial
FEATURING
Othman Al-Sawaf
- 16 views
- September 2, 2021
ecancer
EHA 2021 Primary Analysis From the OPTIC Trial on CP-CML: A Dose-Ranging Study of Ponatinib
FEATURING
Jorge Cortés
- 27 views
- September 2, 2021
ecancer
EHA 2021 Update on Fixed-Duration Ibrutinib and Venetoclax for 1L CLL: Primary Analysis of the GLOW Study
FEATURING
Arnon Kater
- 12 views
- September 2, 2021
ecancer
EHA 2021 Update on Blinatumomab for MRD-Positive B-Cell ALL
FEATURING
Nicholas Short
- 17 views
- September 2, 2021
ecancer
EHA 2021 Update on Blinatumomab + Ponatinib for Ph+ ALL: Interim Results of a Phase II Study
FEATURING
Nicholas Short
- 127 views
- September 2, 2021
- 1
ecancer
EHA 2021 Update on KTE-X19, an Anti-CD19 CAR T-Cell Therapy for R/R B-Cell ALL: ZUMA-3 Trial
FEATURING
Bijal Shah
- 68 views
- September 2, 2021
